Stockscreener 앱 받기
3.40
3.41%
-0.12
전일 마감가:
$3.52
열려 있는:
$3.5
하루 거래량:
125.91K
Relative Volume:
0.09
시가총액:
$16.29M
수익:
$14.50M
순이익/손실:
$-15.41M
주가수익비율:
-4.7887
EPS:
-0.71
순현금흐름:
$-13.04M
1주 성능:
+17.65%
1개월 성능:
+28.30%
6개월 성능:
+61.90%
1년 성능:
-19.59%
1일 변동 폭
$3.2943
$3.60
1주일 범위
$2.80
$3.6399
52주 변동 폭
$1.91
$48.79
비보스 테라퓨틱스 Stock (VVOS) Company Profile
명칭
Vivos Therapeutics Inc
전화
(866)908-4867
주소
7921 SOUTHPARK PLAZA,, LITTLETON
VVOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
3.40 | 16.29M | 14.50M | -15.41M | -13.04M | -0.71 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
비보스 테라퓨틱스 주식(VVOS)의 최신 뉴스
Sleep Apnea: Vivos' FDA-Cleared Technology Offers Revolutionary, Non-Invasive Hope for America's Stealth Epidemic - PR Web
Medicare to reimburse for Vivos CARE sleep apnea devices - MSN
Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS) - Defense World
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call Transcript - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Vivos Therapeutics Inc - GuruFocus.com
Vivos Therapeutics Inc (VVOS) Quarterly 10-Q Report - Quartzy
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones - TipRanks
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 - Proactive Investors USA
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Q3 Revenue Jumps 17% as FDA Approves Pediatric OSA Treatment | VVOS Stock News - StockTitan
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - The Manila Times
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely - Simply Wall St
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance - MSN
Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes - Proactive Investors Australia
Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM - Yahoo Finance
Vivos Granted Reimbursement Codes for Oral Appliances for OSA - Sleep Review
Vivos secures new AMA medical codes for OSA devices - Investing.com
Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments - Stocks Telegraph
Vivos secures new AMA medical codes for OSA devices By Investing.com - Investing.com South Africa
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - The Manila Times
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment - Proactive Investors UK
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive financial news
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics surges on FDA approval for youth sleep apnea treatment device - Mugglehead
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
비보스 테라퓨틱스 (VVOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
자본화:
|
볼륨(24시간):